Catalytic Metallopeptide Promoted Inactivation of Enzyme Targets Related to Disease: Angiotensin Converting Enzyme-1 and SortaseA
Year: 2012
Type: article
Abstract: The use of metal ions and complexes as tools for investigation of protein properties and interactions, as biomarkers for cellular chemistry, as well as therapeutic intervention, have emerged as major new focal points of investigation in inorganic chemistry.Early applications included the design of artificial nucleases and proteases, making use of site-selective binding to amino acid residues and metal-assisted proteolysis.However, redox active metals were also found to promote oxidative modification of amino acid side chains, including hydroxylation and carbonylation of amino acid side chains and protein cross-linking, as well as oxidative damage of nucleic acid bases and sugars, with the potential for subsequent backbone or strand cleavage, have all been observed.While many pathways to improving such modification chemistry have been explored, studies suggest that improvement of metal complex binding to the reactant molecule is an important, if not the major factor in promoting efficient chemistry.In this dissertation we present a novel application of transition metal complexes as catalytic metallodrugs to promote catalytic inactivation on protein related to disease.Herein Angiotensin Converting Enzyme-1 (ACE-1) and SortaseA (SrtA) were studied as they are involved in serious health problems.ACE-1 plays an important role in cardiovascular disease and the current treatment is based on the classical competitive inhibitor which requires high affinity binding and saturated concentration of the drugs to inhibit the function of enzyme.Herein we iii developed series of lisinopril-coupled transition metal chelates which posses the potential for highly efficient multiple-turnover and irreversible inactivation of ACE-1.Interestingly these compounds also demonstrate domain-selective reversible inhibition and domain-selective irreversible inactivation as the two highly homologous domains of ACE-1 share 60% sequence identity.The studies were performed by use of three different fluorogenic substrates which posses different domain selectivity and the kinetic parameters (K I (derived from IC 50 ), rates of inactivation and rates of protein cleavage) were also characterized.However, as limitations on the amount of a commercial ACE-1, we have developed an overexpression system to investigate more details on protein modifications and cleavage.We successfully overexpresssed the analog of cACE in yeast system and further studies on this overexpressed protein are ongoing.SrtA is a key role in the initial step for bacterial infection; hence the interruption of this process can be an approach to develop a novel anti-infective drug.Herein we were able to demonstrate that our catalytic metallopeptides efficiently inactivated SrtA through the oxidative modifications on the active-site cysteine and histidine.
Author: Lalintip Hocharoen
Institution: The Ohio State University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2527630815
